Horizon Therapeutics announced that the FDA has approved an update to the Indications and usage section of the Tepezza label to specify its use for the treatment of "Thyroid Eye Disease regardless of Thyroid Eye Disease activity or duration."
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on HZNP:
- Horizon announces results from Tepezza trial in patients with CAS, TED
- Viridian Therapeutics initiated with a Buy at Stifel
- Horizon Therapeutics presents MRI imaging data from Phase 3 trial of UPLIZNA
- Wells Fargo upgrades Amgen to Overweight, lowers target to $265
- Horizon Therapeutics announces results from real-world analysis of TEPEZZA